We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tyratech (DI/S) | LSE:TYR | London | Ordinary Share | COM SHS USD0.001 (DI / REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.95 | 2.70 | 3.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMTYR TIDMTYRU
RNS Number : 5366J
TyraTech, Inc.
08 April 2015
TyraTech, Inc.
("TyraTech" or the "Company")
Vamousse(R) head lice treatment now distributed by Walgreens in the USA
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products, is pleased to announce that it has secured a listing for its Vamousse Treatment product with Walgreens in the USA.
Walgreens
Through the merger of Walgreens and Alliance Boots completed in December 2014, Walgreens Boots Alliance is now the first global pharmacy-led, health and wellbeing enterprise in the world. In the USA, Walgreens is the largest pharmacy chain with more than 8,000 stores. The Walgreens listing, which follows the recent announcement of the Vamousse listing with CVS as well as with the top three pharmaceutical distributors in the USA, represents an additional key milestone for the roll-out of TyraTech's Vamousse products in the USA. It is expected that the Vamousse Treatment product will be available in the majority of Walgreens stores nationwide in the USA from May 2015.
Bruno Jactel, Chief Executive Officer, said: "The Walgreens listing, following the recent CVS listing and the listing with Walmart last year will put our Vamousse head lice treatment in three of the top four pharmacy retailers in the USA. This is a significant step in the implementation of our strategy of making our products widely available to customers and building a national brand in the US. The TyraTech team is committed, more than ever, to building a brand, expanding distribution for our Vamousse products and creating value for our shareholders.
Further information on Vamousse(R) is available on the Company's website at http://www.vamousselice.com/
TyraTech Inc. Bruno Jactel, Chief Executive Tel: +1 919 Officer 415 4340 Vincent T. Morgus, Chief Tel: +1 919 Financial Officer & Treasurer 415 4287 SPARK Advisory Partners Limited, Tel: +44203 Nominated Adviser 368 3552 Matt Davis / Mark Brady Tel: +44203 368 3551 Allenby Capital Limited , Joint Broker Tel: +44 20 Chris Crawford 3328 5656 Whitman Howard Limited, Joint Broker Tel: +44 20 Ranald Mc-Gregor Smith / 7659 1240 Niall Devins Walbrook, Financial PR and IR Tel: +44 20 Nick Rome /Guy McDougall 7933 8790
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMGGDKNMGKZM
1 Year Tyratech Chart |
1 Month Tyratech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions